Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06990295 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Focused Ultrasound Spleen Stimulation and Inflammation in Septic Shock

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Trial status: Not Yet Recruiting to Recruitingv3 Show 5 more changesShow less
    • Primary and study completion dates: Jul 2, 2026 to Dec 31, 2026
    • Study sites: 0 to 1
    • Start date changed from estimate of Jul 3, 2025 to Jul 25, 2025
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description shortened, about 2 words
  2. Notable Start date: May 28, 2025 to Jul 3, 2025v2 Show 5 more changesShow less
    • Primary completion date: Mar 27, 2026 to Jul 2, 2026
    • Study completion date: May 27, 2026 to Jul 2, 2026
    • Secondary endpoints: details revised at 1 of 4 entries
    • Study description expanded, about 229 words
    • Collaborators expanded, about 5 words
  3. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study evaluates the safety and effectiveness of focused ultrasound spleen neuromodulation in patients with septic shock, a life-threatening condition characterized by excessive inflammation and organ dysfunction. The primary objective is to determine whether non-invasive, focused ultrasound stimulation of the spleen can reduce circulating inflammatory cytokine levels in this patient population. Eligibility Criteria: Adults aged 18 years or older Diagnosed with septic shock and admitted to the ICU within 24 hours Expected to require intensive care for at least 72 hours Study Protocol: Participants will be randomly assigned to one of two groups: Intervention Group: Will receive standard septic shock care plus twice-daily focused ultrasound stimulation over the spleen for five days, using a portable device. Control Group: Will receive standard septic shock care alone. Blood samples will be collected at baseline and Day 5 to measure inflammatory cytokine levels, including TNF-α, IL-1β, IL-6, and IL-10. Additional assessments will include lymphocyte subpopulations, organ function scores, ICU length of stay, 28-day mortality, and adverse events. Outcome Measures: Primary: Change in levels of inflammatory cytokines on Day 5. Secondary: Changes in organ function (SOFA score), ICU length of stay, 28-day survival, and safety/tolerability of the intervention.
Trial Details
NCT Number NCT06990295
Lead Sponsor First Affiliated Hospital of Wannan Medical College
Collaborators: Wuhu City Second People's Hospital
Conditions
(from sponsor)
Septic Shock, Inflammatory Cytokines, Spleen Neuromodulation, Focused Ultrasound, Critical Care
Related terms Shock, Septic
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov